<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192488</url>
  </required_header>
  <id_info>
    <org_study_id>1702396373</org_study_id>
    <nct_id>NCT03192488</nct_id>
  </id_info>
  <brief_title>Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia</brief_title>
  <official_title>Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec®
      use can improve exercise performance of active individuals when acutely exposed to altitude.
      For this project, healthy subjects will perform steady state and progressive work rate
      exercise, endurance performance time trials, and repeated sprint performance time trials in
      the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of
      Cetirizine or a placebo in a repeated measures design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec®
      use can improve exercise performance of active individuals when acutely exposed to altitude.
      For this project, healthy subjects will perform steady state and progressive work rate
      exercise, endurance performance time trials, and repeated sprint performance time trials in
      the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of
      Cetirizine or a placebo in a repeated measures design. Non-invasive techniques (pulse
      oximetry, near-infrared spectroscopy [NIRS]) will be utilized to measure changes in arterial
      oxyhemoglobin saturation and skeletal muscle oxygenation at the level of the microvasculature
      during exercise. It is expected that after Cetirizine, blood and muscle microvascular
      oxygenation during heavy exercise will improve compared to placebo, ultimately improving
      exercise performance at altitude. Subjects will be asked to report to the laboratory on a
      three occasions, separated by a minimum of 48 hours and a maximum of 14 days. For each
      subject, all testing sessions will be performed at the same time of day. Prior to each
      testing session, subjects will be asked to abstain from caffeine consumption for 12 hours.
      Subjects will also be asked to avoid alcohol consumption for 24 hours before testing, be at
      least 3-hour post prandial and avoid high-intensity exercise during the 24 hours leading to
      the exercise testing. Finally, subjects will be asked to consume a similar diet the night
      before, and the morning of, Sessions 2 and 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Actual">June 6, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Time</measure>
    <time_frame>Performed 60min after pill ingestion</time_frame>
    <description>Time to complete 8km cycling time trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Histamine Concentrations at Baseline and Post-Exercise</measure>
    <time_frame>baseline and immediately post-exercise, same day as pill ingestion</time_frame>
    <description>Plasma histamine concentrations (ng/mL) were determined baseline and post-exercise for each experimental condition. Baseline measures were taken immediately prior to exercise and the post-exercise measures were taken 5-10 minutes after the cessation of exercise.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hypoxia, Altitude</condition>
  <arm_group>
    <arm_group_label>Cetirizine/Hypoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Normoxia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Hypoxia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine</intervention_name>
    <description>Cetirizine tablet 10 mg</description>
    <arm_group_label>Cetirizine/Hypoxia</arm_group_label>
    <other_name>Zyrtec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Gelatin placebo</description>
    <arm_group_label>Placebo/Hypoxia</arm_group_label>
    <arm_group_label>Placebo/Normoxia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxia</intervention_name>
    <description>Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft</description>
    <arm_group_label>Cetirizine/Hypoxia</arm_group_label>
    <arm_group_label>Placebo/Hypoxia</arm_group_label>
    <other_name>altitude, low-oxygen environment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically active a minimum of 120 minutes a week, as determined by questionnaire

          -  18-35 years of age

          -  Classified as low risk, based on the modified PAR-Q questionnaire, BMI, and
             non-smoking status

          -  No history of pulmonary disease and pulmonary function classified as normal, as
             defined by the following measurements being 80% of predicted values: forced vital
             capacity (FVC), forced expired volume in one second (FEV1) and FEV1/FVC, according to
             the American Thoracic Society standards.

        Exclusion Criteria:

          -  Current smoker

          -  Women who are pregnant or could possibly be pregnant

          -  BMI &gt; 25 kg/m2

          -  A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire

          -  History of pulmonary disease or &lt;80% of predicted FCV, FEV1 and/or FEV1/FVC.

          -  A history of renal or liver disease, due to possible interaction effect with
             Cetirizine

          -  Currently taking any prescription or over the counter medications for the treatment of
             allergies, or taking any of the below listed drugs known to have a moderate or higher
             interaction effect with Cetirizine:

        isocarboxazid tranylcypromine bosutinib clobazam crizotinib daclatasvir eliglustat
        hyaluronidase lomitapide lurasidone ombitasvir/paritaprevir/ritonavir phenelzine ponatinib
        ritonavir vemurafenib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Chapman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <results_first_submitted>May 7, 2019</results_first_submitted>
  <results_first_submitted_qc>June 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2020</results_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Robert Chapman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD plan</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03192488/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited by direct email to the administrators of the Indiana University ROTC program. It was made clear that participation of cadets was voluntary in nature and was not be a requirement of ROTC duties. Active recruitment took place from 08/2017 to 03/2018.</recruitment_details>
      <pre_assignment_details>Enrolled participants were excluded prior to arm/group assignment if they had abnormal pulmonary function, or voluntarily discontinued with study procedures after completing a graded maximal exercise test and familiarization trial of exercise performance tests on a cycle ergometer. Two subjects withdrew prior to initial group assignments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetirizine/Hypoxia, Placebo/Hypoxia, Placebo/Normoxia</title>
          <description>During the first visit, subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the second visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the third visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Hypoxia, Placebo/Normoxia, Cetirizine/Hypoxia</title>
          <description>During the first visit, subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the second visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
For the third visit, subjects orally ingested 10 mg Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Normoxia, Cetirizine/Hypoxia, Placebo/Hypoxia</title>
          <description>During the first visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
For the second visit, subjects orally ingested 10 mg Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the third visit, subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).</description>
        </group>
        <group group_id="P4">
          <title>Cetirizine/Hypoxia, Placebo/Normoxia, Placebo/Hypoxia</title>
          <description>During the first visit, subjects orally ingested 10 mg Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the second visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
For the third visit, subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Normoxia, Placebo/Hypoxia, Cetirizine/Hypoxia</title>
          <description>During the first visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
For the second visit, subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
During the third visit, subjects orally ingested 10 mg Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).</description>
        </group>
        <group group_id="P6">
          <title>Placebo/Hypoxia, Cetirizine/Hypoxia, Placebo/Normoxia</title>
          <description>During the first visit, subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the second visit, subjects orally ingested 10 mg Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
For the third visit, subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (d1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Washout (&gt;6d)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (d1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Washout (&gt;6d)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (d1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline characteristics for subjects completing all three study arms (Hypoxia/Cetirizine, Hypoxia/Placebo, Normoxia/Placebo) are included.</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects Completing All 3 Study Arms</title>
          <description>Completed: Hypoxia/ Cetirizine (14.3% oxygen with 10mg cetirizine), Hypoxia/ Placebo (21% oxygen with gelatin placebo), and Normoxia/Placebo (21% oxygen with gelatin placebo)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Fat Percentage</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximal Aerobic Capacity (VO2max)</title>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical Activity</title>
          <units>minutes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441" spread="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Performance Time</title>
        <description>Time to complete 8km cycling time trial</description>
        <time_frame>Performed 60min after pill ingestion</time_frame>
        <population>Subjects who completed all three interventions were included in the outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetirizine and Hypoxia</title>
            <description>10 mg of Cetirizine given 60 min before exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Cetirizine: Cetirizine tablet 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Hypoxia</title>
            <description>Placebo given 60 min prior to exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Placebo oral capsule: Gelatin placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Normoxia</title>
            <description>Placebo given 60 min prior to exercise in a normobaric room-air environment (21% oxygen).
Placebo oral capsule: Gelatin placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Time</title>
          <description>Time to complete 8km cycling time trial</description>
          <population>Subjects who completed all three interventions were included in the outcome analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.03" spread="1.92"/>
                    <measurement group_id="O2" value="18.08" spread="2.87"/>
                    <measurement group_id="O3" value="16.32" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANOVA</method>
            <method_desc>The overall model was adjusted for the co-variate &quot;VO2max.&quot;</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Histamine Concentrations at Baseline and Post-Exercise</title>
        <description>Plasma histamine concentrations (ng/mL) were determined baseline and post-exercise for each experimental condition. Baseline measures were taken immediately prior to exercise and the post-exercise measures were taken 5-10 minutes after the cessation of exercise.</description>
        <time_frame>baseline and immediately post-exercise, same day as pill ingestion</time_frame>
        <population>Subjects included are those who completed all three intervention visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetirizine and Hypoxia (Baseline)</title>
            <description>10mg Cetirizine given 60 min prior to exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Placebo oral capsule: 10 mg Cetirizine Histamine: assessed 60 min after pill ingestion, prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Cetirizine and Hypoxia (Post-Exercise)</title>
            <description>10mg Cetirizine given 60 min prior to exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Placebo oral capsule: 10 mg Cetirizine Histamine: assessed 60 min after pill ingestion, 5-10 min after 8km time trial exercise</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Hypoxia (Baseline)</title>
            <description>Placebo given 60 min prior to exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Placebo oral capsule: gelatin placebo Histamine: assessed 60 min after pill ingestion, prior to exercise</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Hypoxia (Post-Exercise)</title>
            <description>Placebo given 60 min prior to exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Placebo oral capsule: gelatin placebo Histamine: assessed 60 min after pill ingestion, 5-10 after 8km time trial exercise</description>
          </group>
          <group group_id="O5">
            <title>Placebo and Normoxia (Baseline)</title>
            <description>Placebo given 60 min prior to exercise in a normobaric room-air environment (21% oxygen).
Placebo oral capsule: gelatin placebo Histamine: assessed 60 min after pill ingestion, prior to exercise</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Normoxia (Post-Exercise)</title>
            <description>Placebo given 60 min prior to exercise in a normobaric room-air environment (21% oxygen).
Placebo oral capsule: gelatin placebo Histamine: assessed 60 min after pill ingestion, 5-10 min following 8km time trial exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Histamine Concentrations at Baseline and Post-Exercise</title>
          <description>Plasma histamine concentrations (ng/mL) were determined baseline and post-exercise for each experimental condition. Baseline measures were taken immediately prior to exercise and the post-exercise measures were taken 5-10 minutes after the cessation of exercise.</description>
          <population>Subjects included are those who completed all three intervention visits.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread=".14"/>
                    <measurement group_id="O2" value=".49" spread=".21"/>
                    <measurement group_id="O3" value=".56" spread=".39"/>
                    <measurement group_id="O4" value=".61" spread=".34"/>
                    <measurement group_id="O5" value=".37" spread=".09"/>
                    <measurement group_id="O6" value=".47" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.327</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.557</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at the time of each intervention visit and for a period of up to one month following each intervention visit date.</time_frame>
      <desc>The definition of adverse event and/or serious adverse event does not differ from clinicaltrials.gov definitions. All-cause mortality was monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cetirizine and Hypoxia</title>
          <description>10 mg of Cetirizine given 60 min before exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Cetirizine: Cetirizine tablet 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Hypoxia</title>
          <description>Placebo given 60 min prior to exercise in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
Placebo oral capsule: Gelatin placebo</description>
        </group>
        <group group_id="E3">
          <title>Placebo and Normoxia</title>
          <description>Placebo given 60 min prior to exercise in a normobaric room-air environment (21% oxygen).
Placebo oral capsule: Gelatin placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fainting</sub_title>
                <description>Lightheadedness and fainting episode with blood draw procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Chapman</name_or_title>
      <organization>Indiana University</organization>
      <phone>812-856-2452</phone>
      <email>rfchapma@indiana.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

